Insmed
INSM

Insmed (INSM) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$220.00Oct 12, 2026
Wolfe ResearchDowngradedOutperform → Peer Perform—Oct 12, 2026
BarclaysMaintainedOverweight$207.00 from $237.00Sep 30, 2026
Goldman SachsMaintainedBuy$188.00Sep 24, 2026
Roth CapitalMaintainedBuy$198.00 from $212.00Sep 15, 2026
Truist SecuritiesMaintainedBuy$195.00 from $185.00Aug 10, 2026
JP MorganMaintainedOverweight$175.00 from $179.00Aug 10, 2026
Wells FargoMaintainedOverweight$169.00 from $161.00Aug 7, 2026
Evercore ISI GroupMaintainedOutperform$170.00 from $160.00Aug 7, 2026
GuggenheimMaintainedBuy$205.00 from $207.00Aug 7, 2026
BMO CapitalInitiated CoverageOutperform$192.00Jul 21, 2026
Wells FargoMaintainedOverweight$161.00 from $160.00Jul 15, 2026
GuggenheimMaintainedBuy$207.00Jul 10, 2026
Evercore ISI GroupMaintainedOutperform$160.00 from $162.00Jun 22, 2026
JP MorganMaintainedOverweight$179.00 from $180.00Jun 8, 2026
RBC CapitalMaintainedOutperform$195.00 from $205.00Jun 5, 2026
Truist SecuritiesMaintainedBuy$185.00 from $205.00May 14, 2026
GuggenheimMaintainedBuy$226.00 from $230.00May 8, 2026
Wells FargoMaintainedOverweight$160.00 from $177.00May 8, 2026
RBC CapitalMaintainedOutperform$205.00 from $220.00May 8, 2026

Frequently asked questions

  • What is the latest analyst rating on INSM?

    On Oct 12, 2026, HC Wainwright & Co. maintained Insmed at Buy with a price target of $220.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.